Application – The Chronic Granulomatous Disease (CGD) Treatment market is primarily divided into three application segments: prophylactic therapy, acute infection management, and curative gene therapy. Prophylactic therapy accounts for the largest share, driven by the need to prevent recurrent bacterial and fungal infections in diagnosed patients; this segment includes long‑term antibiotics and antifungal agents administered continuously. Acute infection management represents a smaller yet critical portion, encompassing short‑term, high‑intensity antimicrobial regimens deployed during breakthrough infections, often in hospital settings. Curative gene therapy is an emerging application, targeting the underlying genetic defect through ex vivo or in vivo vector‑based approaches; although still in clinical trial phases, it is projected to expand rapidly as regulatory approvals materialize. Together, these applications define the overall market size by allocating revenue streams according to treatment duration, intensity, and innovation stage, forming the basis of the Chronic Granulomatous Disease (CGD) Treatment segmentation analysis.